Molecular Imaging in the Era of Personalized Medicine

Clinical imaging creates visual representations of the body interior for disease assessment. The role of clinical imaging significantly overlaps with that of pathology, and diagnostic workflows largely depend on both fields. The field of clinical imaging is presently undergoing a radical change through the emergence of a new field called molecular imaging. This new technology, which lies at the intersection between imaging and molecular biology, enables noninvasive visualization of biochemical processes at the molecular level within living bodies. Molecular imaging differs from traditional anatomical imaging in that biomarkers known as imaging probes are used to visualize target molecules-of-interest. This ability opens up exciting new possibilities for applications in oncologic, neurological and cardiovascular diseases. Molecular imaging is expected to make major contributions to personalized medicine by allowing earlier diagnosis and predicting treatment response. The technique is also making a huge impact on pharmaceutical development by optimizing preclinical and clinical tests for new drug candidates. This review will describe the basic principles of molecular imaging and will briefly touch on three examples (from an immense list of new techniques) that may contribute to personalized medicine: receptor imaging, angiogenesis imaging, and apoptosis imaging.

[1]  Eun Jeong Lee,et al.  Annexin V Imaging Detects Diabetes-Accelerated Apoptosis and Monitors the Efficacy of Benfotiamine Treatment in Ischemic Limbs of Mice , 2014, Molecular imaging.

[2]  Wolfgang A Weber,et al.  Technology Insight: advances in molecular imaging and an appraisal of PET/CT scanning , 2008, Nature Clinical Practice Oncology.

[3]  Yasuyoshi Watanabe,et al.  [Molecular imaging for drug development]. , 2007, Brain and nerve = Shinkei kenkyu no shinpo.

[4]  M. Verheij,et al.  Prognostic significance of 99mTc Hynic-rh-annexin V scintigraphy during platinum-based chemotherapy in advanced lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Kyung-Han Lee,et al.  Radiolabeled RGD uptake and alphav integrin expression is enhanced in ischemic murine hindlimbs. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  Rebecca Richards-Kortum,et al.  Advances in molecular imaging: targeted optical contrast agents for cancer diagnostics. , 2012, Nanomedicine.

[7]  E. Ritman,et al.  Molecular imaging in small animals—roles for micro‐CT , 2002, Journal of cellular biochemistry. Supplement.

[8]  Harvey R Herschman,et al.  Molecular Imaging: Looking at Problems, Seeing Solutions , 2003, Science.

[9]  A. Haimovitz-Friedman,et al.  Anticancer therapy and apoptosis imaging. , 2012, Experimental oncology.

[10]  Julie Hoggatt,et al.  Personalized medicine--trends in molecular diagnostics: exponential growth expected in the next ten years. , 2011, Molecular diagnosis & therapy.

[11]  Kyung-Han Lee,et al.  Targeted in vivo imaging of angiogenesis: present status and perspectives. , 2007, Current pharmaceutical design.

[12]  Neal Rosen,et al.  Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors , 2004, Nature Biotechnology.

[13]  Hedvig Hricak,et al.  Molecular imaging for personalized cancer care , 2012, Molecular oncology.

[14]  Kyung-Han Lee,et al.  99mTc-Hydrazinonicotinamide Epidermal Growth Factor–Polyethylene Glycol–Quantum Dot Imaging Allows Quantification of Breast Cancer Epidermal Growth Factor Receptor Expression and Monitors Receptor Downregulation in Response to Cetuximab Therapy , 2011, The Journal of Nuclear Medicine.

[15]  Thomas E Yankeelov,et al.  Magnetic resonance in the era of molecular imaging of cancer. , 2011, Magnetic resonance imaging.

[16]  Andrei Iagaru,et al.  Imaging tumor angiogenesis: the road to clinical utility. , 2013, AJR. American journal of roentgenology.

[17]  G. Ginsburg,et al.  The path to personalized medicine. , 2002, Current opinion in chemical biology.

[18]  Favorable biokinetic and tumor-targeting properties of 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  Kimberly A Kelly,et al.  Techniques for Molecular Imaging Probe Design , 2011, Molecular imaging.

[20]  David A Mankoff,et al.  Tumor Receptor Imaging , 2008, Journal of Nuclear Medicine.

[21]  R. Djaldetti,et al.  Assessment of response of brain metastases to radiotherapy by PET imaging of apoptosis with 18F-ML-10 , 2012, European Journal of Nuclear Medicine and Molecular Imaging.